The present study suggests that administration of the dual vectors at an optimized ratio, perhaps being personalized for the p53 expression in an individual tumor, can broaden therapeutic options for esophageal carcinoma, which includes further combination with chemotherapy and radiotherapy. Here, TP53 is linked to neoplasm.